We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today:
Fujita et al. have offered an update on the possible value of endoglin or CD105 in urine and in the blood as a biologic marker of risk for or progression of prostate cancer. This possibility is still at the very earliest stages of research at the present time.
Shappell et al. have published early data on the pattterns of use of the PCA3 urine test by community urologists as a method for differentiating between patients with an elevated PSA level and a negative biopsy who may be most appropriate for a repeat biopsy.
Ravizzini et al. have reviewed “new horizons” in prostate cancer imaging and the potential uses of new technologies in the diagnosis and staging of localized prostate cancer.